Business Description
Benitec Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US0820533075
Share Class Description:
FRA:BJ93: Ordinary SharesTotal Employee Number:
19Description
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 210.91 | |||||
Equity-to-Asset | 0.98 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 68.6 | |||||
3-Year EPS without NRI Growth Rate | 69.6 | |||||
3-Year FCF Growth Rate | 73 | |||||
3-Year Book Growth Rate | -14.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -5.52 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 56.82 | |||||
Quick Ratio | 56.82 | |||||
Cash Ratio | 56.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -279.3 | |||||
Shareholder Yield % | -0.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -31.51 | |||||
ROA % | -30.61 | |||||
ROIC % | -2403.59 | |||||
3-Year ROIIC % | -48797.96 | |||||
ROC (Joel Greenblatt) % | -4745.98 | |||||
ROCE % | -35.22 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.43 | |||||
Price-to-Tangible-Book | 2.43 | |||||
EV-to-EBIT | -5.63 | |||||
EV-to-EBITDA | -5.69 | |||||
EV-to-Forward-EBITDA | -0.02 | |||||
EV-to-FCF | -13.26 | |||||
| Price-to-Net-Current-Asset-Value | 2.45 | |||||
| Price-to-Net-Cash | 2.47 | |||||
Earnings Yield (Greenblatt) % | -17.76 | |||||
FCF Yield % | -4.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Benitec Biopharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.799 | ||
| Beta | -0.1023 | ||
| 3-Year Sharpe Ratio | -1.15 | ||
| 3-Year Sortino Ratio | -1.11 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 3.06 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 3.06 - 3.06 | ||
| Shares Outstanding (Mil) | 34.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Benitec Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Benitec Biopharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-01 13:00 | In 140 days | ||
| First quarter earnings results for 2027 | 2026-11-13 | In 121 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-22 16:05 | In 70 days | ||
| Annual report for 2026 | 2026-09-22 | In 69 days | ||
| Third quarter earnings results for 2026 | 2026-05-14 | 3.06 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-12 | 3.06 (+0.00%) | ||
| General meeting for 2025 | 2025-12-01 13:00 | 3.06 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-11-14 | 3.06 (+0.00%) | ||
| Interim BB-301 Phase 1b/2a Clinical Study Update | 2025-11-03 08:00 | 3.06 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-09-22 16:05 | 3.06 (+0.00%) |
Show
Entries
Benitec Biopharma Inc Frequently Asked Questions
What is Benitec Biopharma Inc(FRA:BJ93)'s stock price today?
The current price of FRA:BJ93 is €3.06. The 52 week high of FRA:BJ93 is €3.06 and 52 week low is €3.06.
When is next earnings date of Benitec Biopharma Inc(FRA:BJ93)?
The next earnings date of Benitec Biopharma Inc(FRA:BJ93) is 2026-09-22 Est..
Does Benitec Biopharma Inc(FRA:BJ93) pay dividends? If so, how much?
Benitec Biopharma Inc(FRA:BJ93) does not pay dividend.
Press Release
Articles on Benitec Biopharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers